Paul Meister Joins Quanterix Board Of Directors
Lexington, Mass., August 15, 2013 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Paul Meister to its Board of Directors.
Mr. Meister is the co-founder of Liberty Lane Partners, LLC, a private investment company with diverse investments in healthcare and distribution-related industries. Liberty Lane Partners is part of an investment group that acquired inVentiv Health, a leading provider of commercial, consulting and clinical research services to the pharmaceutical and biotech industries in August 2010 where he now serves as the Chairman and Chief Executive Officer.
He also previously served as Chairman of the Board of Thermo Fisher Scientific Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo. Mr. Meister is also Co-Chair of the University of Michigan’s Life Sciences Institute External Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University.
“We’re very excited to have someone of Paul’s executive caliber joining the Quanterix Board of Directors,” said Paul Chapman, President and Chief Executive Officer of Quanterix. “Paul’s extensive commercial experience couldn’t have come at a better time for Quanterix given that we recently commercialized the Simoa platform and are poised to have a steep ramp in sales.”
“The Simoa technology that the Quanterix team has developed represents a significant advancement in life science research,” Meister said. “I am convinced it will open the door to important discoveries that could improve human health, and am pleased to be joining the Board just as Quanterix is poised for expansion into the marketplace.”
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.
Nikki Festa/Caitlyn Keating
Share this page